全文获取类型
收费全文 | 1602092篇 |
免费 | 131251篇 |
国内免费 | 2581篇 |
专业分类
耳鼻咽喉 | 21646篇 |
儿科学 | 52951篇 |
妇产科学 | 46280篇 |
基础医学 | 227784篇 |
口腔科学 | 47201篇 |
临床医学 | 140929篇 |
内科学 | 314802篇 |
皮肤病学 | 34090篇 |
神经病学 | 130121篇 |
特种医学 | 64732篇 |
外国民族医学 | 474篇 |
外科学 | 243797篇 |
综合类 | 39712篇 |
现状与发展 | 3篇 |
一般理论 | 544篇 |
预防医学 | 122859篇 |
眼科学 | 36472篇 |
药学 | 121259篇 |
3篇 | |
中国医学 | 2974篇 |
肿瘤学 | 87291篇 |
出版年
2018年 | 14765篇 |
2016年 | 12900篇 |
2015年 | 15031篇 |
2014年 | 20655篇 |
2013年 | 31354篇 |
2012年 | 42553篇 |
2011年 | 44761篇 |
2010年 | 26345篇 |
2009年 | 25309篇 |
2008年 | 43010篇 |
2007年 | 45247篇 |
2006年 | 46055篇 |
2005年 | 44691篇 |
2004年 | 44097篇 |
2003年 | 42189篇 |
2002年 | 41303篇 |
2001年 | 75689篇 |
2000年 | 78334篇 |
1999年 | 66393篇 |
1998年 | 17733篇 |
1997年 | 16334篇 |
1996年 | 16316篇 |
1995年 | 16024篇 |
1994年 | 15072篇 |
1993年 | 14222篇 |
1992年 | 55434篇 |
1991年 | 53778篇 |
1990年 | 52565篇 |
1989年 | 50837篇 |
1988年 | 47226篇 |
1987年 | 46560篇 |
1986年 | 44286篇 |
1985年 | 42843篇 |
1984年 | 32036篇 |
1983年 | 27566篇 |
1982年 | 16144篇 |
1981年 | 14436篇 |
1980年 | 13564篇 |
1979年 | 30460篇 |
1978年 | 21065篇 |
1977年 | 17764篇 |
1976年 | 16694篇 |
1975年 | 17574篇 |
1974年 | 21486篇 |
1973年 | 20673篇 |
1972年 | 18853篇 |
1971年 | 17770篇 |
1970年 | 16289篇 |
1969年 | 15268篇 |
1968年 | 13949篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
45.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
46.
47.
48.
49.
50.
R. E. J. Ryder 《Diabetic medicine》2015,32(3):305-313
On 8 April 2014, a US jury ordered Takeda and Eli Lilly to pay $9 bn in punitive damages after finding that they had concealed the cancer risks associated with pioglitazone. By contrast, on 28 August 2014, the long‐awaited outcome of the 10‐year Kaiser Permanente Northern California study was announced. That study was specifically designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer and found no association; thus, at last, the controversial issue has been resolved. A review, in retrospect, of the story of the proposed link between pioglitazone and bladder cancer reveals flaws at every stage. In 2012, a BMJ editorial, in keeping with some other contemporary reports, stated ‘it can confidently be assumed that pioglitazone increases the risk of bladder cancer’. Examination of the information which led to such a statement shows that: 1) the pre‐clinical findings of bladder cancer in male rats is not indicative of human risk; 2) there is no association between bladder cancer and pioglitazone in randomized controlled trials, once cases that could not plausibly be related to treatment are removed; and 3) the observational studies that have suggested a link have over‐extrapolated from the data: pioglitazone‐treated patients had more risk factors for bladder cancer than those not treated with pioglitazone. Meanwhile careful study of randomized controlled trials shows evidence of cardiovascular benefit from pioglitazone in Type 2 diabetes, a condition which results, more than anything, in premature cardiovascular death and morbidity. 相似文献